History of OGT

Founded in 1995 by Professor Ed Southern, Oxford Gene Technology (OGT) has rapidly become one of the leading providers of genetics research solutions to customers worldwide.

2018 OGT begins selling Cytocell FISH products through several established affiliates of Sysmex Corporation in Europe
2018 Content further expanded for OGT's custom NGS cancer panel content, now covering 120 fully optimised cancer related genes
2018 John Anson, who has been with the company since 2006 as EVP of R&D, takes over as CEO from Dr Mike Evans
2018 OGT enhances customer experience with new Cytocell website
2017 OGT to be acquired by Sysmex Corporation, a Japanese in vitro diagnostic company.
2017 Content expanded for OGT's SureSeq myPanel NGS Custom Cancer Panels, now covering 70 genes
2016 OGT expands Cytocell sarcoma FISH probe range, with three new probes: FUS Breakapart, FOXO1 Breakapart and TFE3 Breakapart
2016 OGT releases targeted NGS panel to study SNV and CNV in FH
2016 Significant expansion of Cytocell haematology FISH probe range, with the launch of 14 new probes
2016 SureSeq myPanel NGS Custom Cancer Panels launched, providing scientists with completely customised, pre-optimised NGS probe panels relevant to their research
2016 OGT expands pathology FISH probe range with two new probes in its lung cancer portfolio
2016 Expanded range of haematology FISH probes, with 9 new probes added
2016 OGT introduced its SureSeq FFPE DNA Repair Mix — optimised to repair a broad range of damage in formalin-fixed, paraffin-embedded (FFPE) derived DNA.
2016 New 1p36/1q25 and 19q13/19p13 Deletion Probe Kit launched, a cost-effective FISH kit for the reliable investigation of glial tumours.
2016 OGT develops new FISH probes for pig, chicken and mouse in ‘outstanding’ Innovate UK project
2016 OGT expands leading constitutional array range with the launch of the CytoSure Constitutional v3 +LOH array 
2015 OGT expands NGS portfolio with SureSeq Ovarian Cancer Panel and SureSeq Library Preparation Kit
2015 OGT expands its portfolio of Cytocell pathology FISH probes
2015 New SureSeq Myeloid NGS panel launched allowing improved analysis of myeloproliferative neoplasms 
2015 OGT launches new Constitutional v3 array that utilises the latest research to enhance the identification of developmental disorders
2015 OGT scientists collaborate on new test for tuberculosis causing bacteria that reduces time to result from weeks to days
2015 OGT awarded £1.2m Genomics England contract to develop genomic analysis software to enhance clinical decision making and improve patient care
2014 OGT initiates clinical trial of array-based non-invasive prenatal test (NIPT)
2014 OGT launches CytoSure Medical Research Exome array to complement targeted sequencing with gold standard copy number variation detection
2014 OGT awarded SBRI contract to develop innovative NGS analysis software
2014

OGT launches high-resolution, high-throughput PGS array

2014

OGT launches solid tumour next generation sequencing (NGS) panel

2014 OGT expands genomic medicine portfolio with acquisition of Cytocell Ltd.
2014 NHS awards significant cytogenetics tender to OGT
2013 CytoSure Consortium Cancer +SNP array launched for standardised analysis of haematological and solid tumours
2013 OGT launches pre-implantation genetic screening array to improve the chances of successful IVF
2013 OGT launches ground-breaking 58-gene tumour profiling service
2013 OGT releases new CytoSure microarray for cancer research
2013 OGT granted prostate cancer biomarker licence by the ICR
2012 OGT initiates strategic expansion with the opening of New York office.
2012 OGT launches the Genefficiency RNA Sequencing Service
2012 OGT forms Scientific Advisory Board chaired by Peter Rigby, Emeritus Professor of Developmental Biology at the Institute of Cancer Research.
2012 OGT awarded €3 million from prestigious EU clinical research grants to detect and characterise pathogenic infection in clinical samples
2012 CytoSure ISCA +SNP array launched for reliable copy number variation detection combined with accurate identification of loss of heterozygosity (LOH) and uniparental disomy (UPD)
2012

OGT releases first in a new line of cancer microarrays

2012

OGT signs licensing deal for colorectal cancer biomarkers

2012

OGT launches optimised rare disease sequencing and analysis service

2012

OGT founder Professor Sir Ed Southern awarded the MRC Millennium Medal

2011 CytoSure Molecular Testing Arrays and Panels launched to deliver reliable detection of DNA copy number changes for a range of molecular disorders
2011 Working with OGT, NHS targets genotyping for every cancer patient in the UK
2011 Genefficiency Sequencing Services launched offering expert project design and data interpretation

2011

CytoSure HT Genomic DNA Labelling Kit launched for faster, high-throughput sample processing

2011

CytoSure ISCA Sample Tracking Spike-ins launched for easy identification of sample mix-up

2010

CytoSure ISCA UPD array launched — the first ever array combining aCGH probes for enhanced CNV calling with SNP content for detection of uniparental disomy

2010

OGT’s Biomarker Discovery team announce panel of biomarkers offering potential for significantly improved detection of prostate cancer

2010

OGT’s Genefficiency microarray service awarded Agilent High Throughput Certified Service provider status

2010

CytoSure Services launched — a dedicated microarray screening service for cytogenetic samples

2010 OGT awarded ISO27001, highlighting commitment to information security and confidentiality

2010

OGT awarded ISO9001, demonstrating ongoing commitment to providing the highest quality solutions and customer service

2010

CytoSure ISCA arrays launched,  providing a standardised, evidence-based array format for cytogenetic analysis

2010

OGT's Genefficiency Genomic Services awarded 10,000 sample project investigating the relationship between structural variation and susceptibility to type 1 diabetes

2009

Launch of CytoSure Genomic DNA Labelling Kit — optimised for high signal-to-noise ratios

2009

OGT Genefficiency Genomic Services complete the world’ largest copy number variation study for the Wellcome Trust Case Control Consortium — 20,000 samples screened in less than 20 weeks

2009

OGT acquire Sense Proteomic to enhance expertise in diagnostic biomarkers

2009

OGT complement CytoSure portfolio with full automation options from SciGene

2009

CytoSure DMD array launched, allowing accurate detection of Duchenne muscular dystrophy (DMD) and Becker’s muscular dystrophy (BMD)

2008

OGT microarray service awarded Agilent Certified Service Provider status

2008

CytoSure Syndrome Plus v2 and Chromosome X arrays launched

2006

OGT launch the CytoSure range of arrays and analysis software dedicated to cytogenetic analysis

2003

OGT provides its first complete microarray services

1995

Professor Sir Edwin Southern founds Oxford Gene Technology (OGT)

1991 First licensing of DNA microarray patents